Inhibition of Platelet Aggregation by AZD6140, A Reversible Oral P2Y12Receptor Antagonist, Compared With Clopidogrel in Patients With Acute Coronary Syndromes
Top Cited Papers
- 25 October 2007
- journal article
- research article
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 50 (19) , 1852-1856
- https://doi.org/10.1016/j.jacc.2007.07.058
Abstract
No abstract availableKeywords
This publication has 14 references indexed in Scilit:
- Biology and Pharmacology of the Platelet P2Y12 ReceptorCurrent Pharmaceutical Design, 2006
- Clopidogrel Effect on Platelet REactivity in Patients With Stent ThrombosisJournal of the American College of Cardiology, 2005
- Preclinical and Clinical Studies with Selective Reversible Direct P2Y12AntagonistsSeminars in Thrombosis and Hemostasis, 2005
- Clopidogrel Resistance Is Associated With Increased Risk of Recurrent Atherothrombotic Events in Patients With Acute Myocardial InfarctionCirculation, 2004
- Resistance to thienopyridines: Clinical detection of coronary stent thrombosis by monitoring of vasodilator‐stimulated phosphoprotein phosphorylationCatheterization and Cardiovascular Interventions, 2003
- Clopidogrel for Coronary StentingCirculation, 2003
- Management of acute coronary syndromes in patients presenting without persistent ST-segment elevationEuropean Heart Journal, 2002
- Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsBMJ, 2002
- Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment ElevationNew England Journal of Medicine, 2001
- Clopidogrel: a review of its mechanism of actionPlatelets, 1998